Michael York - Net Worth and Insider Trading

Michael York Net Worth

The estimated net worth of Michael York is at least $145 dollars as of 2024-11-05. Michael York is the Chief Business Officer of Metacrine Inc and owns about 103,499 shares of Metacrine Inc (MTCR) stock worth over $145. Michael York is also the VP, Corporate Development of PhaseBio Pharmaceuticals Inc and owns about 1,500 shares of PhaseBio Pharmaceuticals Inc (PHASQ) stock worth over $0. Details can be seen in Michael York's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Michael York has not made any transactions after 2023-01-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Michael York

To

Michael York Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael York owns 2 companies in total, including PhaseBio Pharmaceuticals Inc (PHASQ) , and Metacrine Inc (MTCR) .

Click here to see the complete history of Michael York’s form 4 insider trades.

Insider Ownership Summary of Michael York

Ticker Comapny Transaction Date Type of Owner
PHASQ PhaseBio Pharmaceuticals Inc 2020-02-12 VP & Corporate Development
MTCR Metacrine Inc 2023-01-26 Chief Business Officer

Michael York Latest Holdings Summary

Michael York currently owns a total of 2 stocks. Among these stocks, Michael York owns 103,499 shares of Metacrine Inc (MTCR) as of January 26, 2023, with a value of $145 and a weighting of 99.9%. Michael York also owns 1,500 shares of PhaseBio Pharmaceuticals Inc (PHASQ) as of December 11, 2018, with a value of $0 and a weighting of 0.1%.

Latest Holdings of Michael York

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
MTCR Metacrine Inc 2023-01-26 103,499 0.00 145
PHASQ PhaseBio Pharmaceuticals Inc 2018-12-11 1,500 0.00 0

Holding Weightings of Michael York


Michael York Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael York has made a total of 1 transactions in Metacrine Inc (MTCR) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Metacrine Inc is the sale of 107,054 shares on January 26, 2023, which brought Michael York around $43,892.

According to the SEC Form 4 filings, Michael York has made a total of 0 transactions in PhaseBio Pharmaceuticals Inc (PHASQ) over the past 5 years. The most-recent trade in PhaseBio Pharmaceuticals Inc is the acquisition of 1,500 shares on December 11, 2018, which cost Michael York around $5,820.

Insider Trading History of Michael York

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael York Trading Performance

GuruFocus tracks the stock performance after each of Michael York's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael York is -24.87%. GuruFocus also compares Michael York's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael York within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Michael York's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Michael York

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -2.85 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -1.31 LIMIT LIMIT LIMIT LIMIT LIMIT

Michael York Ownership Network

Ownership Network List of Michael York

No Data

Ownership Network Relation of Michael York

Insider Network Chart

Michael York Owned Company Details

What does PhaseBio Pharmaceuticals Inc do?

Who are the key executives at PhaseBio Pharmaceuticals Inc?

Michael York is the VP & Corporate Development of PhaseBio Pharmaceuticals Inc. Other key executives at PhaseBio Pharmaceuticals Inc include 10 percent owner New Enterprise Associates 13 Lp , VP & Human Resources Glen Burkhardt , and Chief Commercial Officer Jonathan Birchall .

PhaseBio Pharmaceuticals Inc (PHASQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PhaseBio Pharmaceuticals Inc (PHASQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

PhaseBio Pharmaceuticals Inc Insider Transactions

No Available Data

Michael York Mailing Address

Above is the net worth, insider trading, and ownership report for Michael York. You might contact Michael York via mailing address: C/o Phasebio Pharmaceuticals, Inc., 1 Great Valley Pkwy., Suite 30, Malvern Pa 19355.